Moleculin Biotech (MBRX) Proxy Filing summary

Executive summary

• Special Meeting of Stockholders scheduled for April 15, 2026, at the company’s Houston offices.

• Stockholders will vote on three key proposals: issuance of shares under warrants, a corporate name change, and potential adjournment to solicit more proxies.

• Board unanimously recommends voting in favor of all proposals.

• Only stockholders of record as of February 20, 2026, are eligible to vote.

• Proxy materials are available electronically, and multiple voting methods are provided.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of up to 6,367,956 shares upon exercise of warrants issued in a private placement, as required by Nasdaq Listing Rule 5635(d).

• Proposal 2: Approve amendment to change the company’s name from Moleculin Biotech, Inc. to Moleculin Inc.

• Proposal 3: Approve adjournment of the meeting if more time is needed to solicit proxies for the above proposals.

• Board recommends voting “FOR” all proposals.

• Quorum is one-third of outstanding shares; each share gets one vote.

Board of directors and corporate governance

• Board and management will be present at the meeting to answer questions.

• Corporate governance information is available on the company’s website.

• Inspector of election appointed to tabulate votes; results to be filed on Form 8-K.